Evidence map›Paper›PMID 41431547›Full record

ReviewCureus2025

Exploring the Interplay Between Hypertension and Osteoporosis: A Narrative Review.

Yolanda Gutierrez, Ronald A Shaju, Alyssa Sepulveda, Seval Coban

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yolanda GutierrezSchool of Medicine, University of Texas Rio Grande Valley School of Medicine, Edinburg, USA.
Ronald A ShajuSchool of Medicine, University of Texas Rio Grande Valley School of Medicine, Edinburg, USA.
Alyssa SepulvedaSchool of Medicine, University of Texas Rio Grande Valley School of Medicine, Edinburg, USA.
Seval CobanSchool of Medicine, University of Texas Rio Grande Valley School of Medicine, Edinburg, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension and osteoporosis are highly prevalent chronic conditions that have significant implications for global health, especially in aging populations. While these conditions have traditionally been viewed as separate, emerging research suggests a strong pathophysiological link between the two. Understanding these shared mechanisms may help improve screening and guide integrated management strategies. This narrative review was conducted between January 2024 and July 2025 using PubMed, ScienceDirect, and Google Scholar. The search strategy used the Boolean string: ("hypertension" OR "high blood pressure") AND ("osteoporosis" OR "bone loss"), supplemented with pharmacologic terms ("ACE inhibitors," "angiotensin receptor blockers," "thiazide diuretics," "beta-blockers", "SERMS", "Bisphosphonates", "Denosumab", "romosozumab", and "teriparatide"). Filters included English language, peer-reviewed human and animal studies when mechanically relevant. A total of 336 articles were retrieved, 143 titles and abstracts were screened, and 61 articles were selected. Data were synthesized qualitatively and organized thematically. Evidence demonstrates that oxidative stress and the renin-angiotensin-aldosterone system (RAAS) activation serve as strong mechanisms linking osteoporosis and hypertension. These pathways promote endothelial dysfunction, osteoclastogenesis, and impaired osteoblast activity. Hormonal disturbances such as estrogen deficiency can further exacerbate both vascular and skeletal deterioration. Several antihypertensive medications, including thiazide diuretics, angiotensin-converting enzyme inhibitors (ACEis), and angiotensin II receptor blockers (ARBs), show bone protective effects; however, most osteoporosis medications exhibit neutral or mixed influence on the cardiovascular system. Hypertension and osteoporosis share connected biological pathways that contribute to both vascular dysfunction and bone loss. Recognizing this connection can encourage therapeutic approaches and address cardiovascular and skeletal health. Further research is needed to define appropriate dual interventions.

Indexed as

anti-hypertensiveschronic disease managmenthypertensionosteoporosispharmacology

Identifiers

PMID41431547
PMCPMC12718624

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.